JAQBO® Tab. 20 mg(Zastaprazan Citrate) in Erosive GERD

Jeil Pharmaceutical

Status: Not yet enrolling

Conditions: Erosive Gastroesophageal Reflux Disease

Study type: Observational

Funder types: Industry

Identifiers

NCT07115706

JL-JAQ-403

Details and patient eligibility

About

The purpose of this study is to evaluate the effectiveness and safety of JAQBO® Tab. 20 mg(Zastaprazan citrate) patients who have been prescribed the investigational drug.

Full description

Multi-center prospective observational study

Enrollment: 7,150 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• subjects aged 19 years or older who have been diagnosed with erosive reflux disease (ERD)
• subjects who have voluntarily decided to participate in this observational study and have provided written informed consent after receiving the study information and consent form

Exclusion criteria

• Subjects who fall under the contraindications listed in the precautions for use section of the approved labeling for Fexuclu tablets:

  1. Subjects with hypersensitivity or a history of hypersensitivity to the investigational drug or any of its components
  2. Subjects currently taking medications containing atazanavir, nelfinavir, or rilpivirine
  3. Pregnant women, women who may be pregnant, or breastfeeding women
  4. Subjects with genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption

• Subjects deemed inappropriate for participation in the study at the investigator's discretion.

Trial design

7,150 participants in 1 patient group

Group1

Description:

those with a condition